Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients.
Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients.
复制标题
DOI：
10.1155/2013/146579
复制
发表时间：
2013-01-01
期刊：
影响因子：
--
通讯作者：
Zirie, Mahmoud
中科院分区：
文献类型：
--
作者：
Barakat, Lolwa;Jayyousi, Amin;Zirie, Mahmoud
目标.在卡塔尔糖尿病患者中研究三种最常用的他汀类药物（瑞舒伐他汀、阿托伐他汀和普伐他汀）治疗血脂异常的疗效和安全性。主题和方法。这项基于人群的回顾性观察性研究纳入了350例连续糖尿病患者，这些患者在2005年9月至2009年9月期间被诊断为血脂异常并处方了任何适用的他汀类药物。通过审查药房数据库、电子病历数据库（EMR查看器）和患者病历收集数据。在基线和第一年和第二年的时间间隔进行了血脂测量的比较。结果瑞舒伐他汀（10 mg）在降低LDL-C方面最有效（29.03%）。阿托伐他汀在40 mg剂量时降低LDL-C最多（22.8%），普伐他汀在20 mg剂量时降低LDL-C最多（20.3%）。所有三种他汀类药物在肌肉和肝功能方面都是安全的。在肾功能方面，阿托伐他汀是最安全的他汀类药物，因为在2年治疗结束时新发微量白蛋白尿的患者数量最少（10.9%），其次是瑞舒伐他汀（14.3%），然后是普伐他汀（26.6%）。结论在卡塔尔背景下，降低LDL-C最有效的他汀类药物是瑞舒伐他汀10 mg。阿托伐他汀是与肾功能相关的最安全的他汀类药物。未来的大规模前瞻性研究需要证实这些结果。
Objectives. To investigate the efficacy and the safety of the three most commonly prescribed statins (rosuvastatin, atorvastatin, and pravastatin) for managing dyslipidemia among diabetic patients in Qatar. Subjects and Methods. This retrospective observational population-based study included 350 consecutive diabetes patients who were diagnosed with dyslipidemia and prescribed any of the indicated statins between September 2005 and September 2009. Data was collected by review of the Pharmacy Database, the Electronic Medical Records Database (EMR viewer), and the Patient's Medical Records. Comparisons of lipid profile measurements at baseline and at first- and second-year intervals were taken. Results. Rosuvastatin (10mg) was the most effective at reducing LDL-C (29.03%). Atorvastatin reduced LDL-C the most at a dose of 40mg (22.8%), and pravastatin reduced LDL-C the most at a dose of 20mg (20.3%). All three statins were safe in relation to muscular and hepatic functions. In relation to renal function, atorvastatin was the safest statin as it resulted in the least number of patients at the end of 2 years of treatment with the new onset of microalbuminuria (10.9%) followed by rosuvastatin (14.3%) and then pravastatin (26.6%). Conclusion. In the Qatari context, the most effective statin at reducing LDL-C was rosuvastatin 10mg. Atorvastatin was the safest statin in relation to renal function. Future large-scale prospective studies are needed to confirm these results.